Filing Flows › Traws Pharma (TRAW) › Q1 2025
Traws Pharma (TRAW) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Traws Pharma (TRAW) reported revenue of $57K for the first quarter 2025 (Q1 2025), +2% from a year earlier and +2% from the quarter before.
Traws Pharma, Q1 2025: revenue $57K (+2% year over year), net earnings $21.5M, operating cash flow −$5.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $57K | +2% | +2% |
| Operating profit | −$5.2M | — | — |
| Net earnings | $21.5M | — | — |
| Operating cash flow | −$5.4M | — | — |
What changed
Revenue was $57K in Q1 2025, up 2% year over year and up 2% from the previous quarter.
Operating costs exceeded revenue by $5.2M, an operating margin of -9128.1%. Total costs fell 0% while revenue rose 2%. The fastest-growing cost line was Research & development (+31%). Net earnings were $21.5M. The effective tax rate was 0.0%. Non-operating items added $26.7M, 124% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$5.4M. Non-cash charges added back $1K of depreciation and amortization and $161K of share-based compensation. Working capital and other items used $27.1M.
Questions
What was Traws Pharma's revenue in the first quarter 2025?
Traws Pharma (TRAW) reported revenue of $57K for the first quarter 2025 (Q1 2025), +2% from a year earlier and +2% from the quarter before.
Source: Traws Pharma 10-Q on SEC EDGAR.